M. Hina , M. Tariq , F. Shakeel , S. Arif , Y. Ahmed , S. Abrar , A. Hafiz , N. Ali , A. Abbasi , B. Qureshi
{"title":"Assessing Acute Side Effects in Hodgkin's Lymphoma Patients Undergoing Radiation Therapy: A Comparison of Sequential and Non-Sequential RT Approaches","authors":"M. Hina , M. Tariq , F. Shakeel , S. Arif , Y. Ahmed , S. Abrar , A. Hafiz , N. Ali , A. Abbasi , B. Qureshi","doi":"10.1016/j.ijrobp.2024.11.038","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>To assess acute effects in radiation therapy (RT) for Hodgkin's Lymphoma (HL) after chemotherapy.</div></div><div><h3>Method</h3><div>HL patients treated from March 2017-January 2024 were retrospectively analyzed. Complete data for 63 out of an initial cohort of 100 patients was identified via a comprehensive review of treatment files and online database. Demographic, RT details along with acute effect profile was recorded.</div></div><div><h3>Result</h3><div>Among patients, 44.4%(n=28) were <10 years, 42.9%(n=27) 10-15 years and 12.7%(n=8) >15 years. Males constituted 77.8%(n=49) and females 22.2%(n=14). There were 3.2%(n=2) Stage I, 33.3%(n=21) Stage II, 38.1%(n=24) Stage III, 25.4%(n=16) Stage IV and 22.2%(n=18) Relapsed/Refractory cases.</div><div>RT included 3D-Conformal Radiation Therapy (3DCRT; 23.8%, n=15) and Intensity Modulated Radiation Therapy/Volumetric Modulated Arc Therapy (IMRT/VMAT; 76.2%, n=48) with a median dose of 2980 cGY in 42.9%(n=27). Sites were categorized into supradiaphragmatic only 30.2%(n=19), concurrent 60.3%(n=38), and infradiaphragmatic only 9.5%(n=6). Frequently treated sites included cervical region (88.95%, n=55), mediastinum (65.1%, n=41), para-aortic (58.7%, n=37), spleen (41.3%, n=26), axilla (39.7%, n=25), inguinal (17.5%, n=11), pelvis (14.3%, n=9) and skeletal region (9.5%, n=6). Among patients with both supra and infra diaphragmatic disease, 74.6% (n=47) received concurrent RT to both regions. Sequential RT for either lesion was done in 25.4% (n=16) patients. The majority (66.7%, n=42) experienced no treatment gaps.</div><div>In sequential RT, 11%(n=7) reported no acute effects, 6.3%(n=4) G1 mucositis, 1.6%(n=1) dysphagia and G1 dermatitis each. In non-sequential RT, 38.1%(n=24) reported no acute effects, 22.2%(n=14) G1 dermatitis, 17.5%(n=11) dysphagia, 11.1%(n=7) G1 mucositis and G2 mucositis each, 9.5%(n=6) vomiting, 7.9%(n=5) nausea, 4.8%(n=3) G2 dermatitis, 1.6%(n=1) G3 mucositis and nodal swelling each.</div></div><div><h3>Conclusion</h3><div>Our study highlights the reduced incidence of acute effects with the introduction of conformal RT techniques. Even among those receiving concurrent supra and infra diaphragmatic RT, majority experienced no acute effects, and those who did, tolerated them well.</div></div>","PeriodicalId":14215,"journal":{"name":"International Journal of Radiation Oncology Biology Physics","volume":"121 3","pages":"Page e10"},"PeriodicalIF":6.4000,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Radiation Oncology Biology Physics","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0360301624036125","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Objective
To assess acute effects in radiation therapy (RT) for Hodgkin's Lymphoma (HL) after chemotherapy.
Method
HL patients treated from March 2017-January 2024 were retrospectively analyzed. Complete data for 63 out of an initial cohort of 100 patients was identified via a comprehensive review of treatment files and online database. Demographic, RT details along with acute effect profile was recorded.
Result
Among patients, 44.4%(n=28) were <10 years, 42.9%(n=27) 10-15 years and 12.7%(n=8) >15 years. Males constituted 77.8%(n=49) and females 22.2%(n=14). There were 3.2%(n=2) Stage I, 33.3%(n=21) Stage II, 38.1%(n=24) Stage III, 25.4%(n=16) Stage IV and 22.2%(n=18) Relapsed/Refractory cases.
RT included 3D-Conformal Radiation Therapy (3DCRT; 23.8%, n=15) and Intensity Modulated Radiation Therapy/Volumetric Modulated Arc Therapy (IMRT/VMAT; 76.2%, n=48) with a median dose of 2980 cGY in 42.9%(n=27). Sites were categorized into supradiaphragmatic only 30.2%(n=19), concurrent 60.3%(n=38), and infradiaphragmatic only 9.5%(n=6). Frequently treated sites included cervical region (88.95%, n=55), mediastinum (65.1%, n=41), para-aortic (58.7%, n=37), spleen (41.3%, n=26), axilla (39.7%, n=25), inguinal (17.5%, n=11), pelvis (14.3%, n=9) and skeletal region (9.5%, n=6). Among patients with both supra and infra diaphragmatic disease, 74.6% (n=47) received concurrent RT to both regions. Sequential RT for either lesion was done in 25.4% (n=16) patients. The majority (66.7%, n=42) experienced no treatment gaps.
In sequential RT, 11%(n=7) reported no acute effects, 6.3%(n=4) G1 mucositis, 1.6%(n=1) dysphagia and G1 dermatitis each. In non-sequential RT, 38.1%(n=24) reported no acute effects, 22.2%(n=14) G1 dermatitis, 17.5%(n=11) dysphagia, 11.1%(n=7) G1 mucositis and G2 mucositis each, 9.5%(n=6) vomiting, 7.9%(n=5) nausea, 4.8%(n=3) G2 dermatitis, 1.6%(n=1) G3 mucositis and nodal swelling each.
Conclusion
Our study highlights the reduced incidence of acute effects with the introduction of conformal RT techniques. Even among those receiving concurrent supra and infra diaphragmatic RT, majority experienced no acute effects, and those who did, tolerated them well.
期刊介绍:
International Journal of Radiation Oncology • Biology • Physics (IJROBP), known in the field as the Red Journal, publishes original laboratory and clinical investigations related to radiation oncology, radiation biology, medical physics, and both education and health policy as it relates to the field.
This journal has a particular interest in original contributions of the following types: prospective clinical trials, outcomes research, and large database interrogation. In addition, it seeks reports of high-impact innovations in single or combined modality treatment, tumor sensitization, normal tissue protection (including both precision avoidance and pharmacologic means), brachytherapy, particle irradiation, and cancer imaging. Technical advances related to dosimetry and conformal radiation treatment planning are of interest, as are basic science studies investigating tumor physiology and the molecular biology underlying cancer and normal tissue radiation response.